Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride, the active ingredient in Mydriasert, is a mydriatic agent presented as an ophthalmic solution for ocular use. It, together with tropicamide, produces rapid pupil dilation to facilitate diagnostic eye examinations and ophthalmic procedures.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mydriasert, a combination mydriatic eye drop, is used in ophthalmology to achieve pupil dilation.

Diagnostic eye examinations: provides sufficient mydriasis to allow thorough retinal evaluation. Ophthalmic surgery: creates a wide pupil for better intra‑operative visualization. Laser ophthalmic procedures: enables adequate exposure of the treatment area during laser therapy.

Mydriasert may cause ocular and systemic reactions after administration.

Common Side Effects: - Transient blurred vision - Mild ocular discomfort or stinging - Conjunctival redness - Photophobia - Temporary increase in intra‑ocular pressure - Mild headache

Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Severe allergic reaction (e.g., rash, swelling) - Systemic hypertension or tachycardia - Cardiac arrhythmia - Ocular inflammation or infection - Persistent mydriasis beyond expected duration

Before using Mydriasert, consider the following safety measures.

Assess intra‑ocular pressure: verify baseline pressure to avoid exacerbating glaucoma. Avoid in narrow‑angle glaucoma: risk of angle‑closure attacks. Use cautiously in hypertensive patients: monitor blood pressure for systemic effects. Monitor children closely: systemic absorption may be higher. Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with other medications; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Systemic alpha‑adrenergic agonists (e.g., phenylephrine nasal spray): additive cardiovascular stimulation. - Concurrent mydriatic agents: risk of excessive pupil dilation. - Monoamine oxidase inhibitors: potential hypertensive crisis.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: enhanced mydriatic effect. - Topical beta‑blocker eye drops: may influence intra‑ocular pressure control. - Local anesthetic eye drops: increased ocular irritation risk.